Tagged with R

basic research The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at the international level.     When was the cabinet was founded and what exactly is its role? The Scientific Technological Cabinet…

hospital The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to become the market leader in Asia by offering a comprehensive range of services for cardiovascular medicine with a wide range…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

R&D Graham Skarnvad arrived to Spain as country manager of ALK’s Spanish affiliate at the end of 2009, right when the crisis was in full swing. Later on he took the full legal responsibility – also as: General Manager for Spain, and Portugal. He discusses his mandate and increased in investment…

commercialization The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina.   Could you please provide an historical overview of Argenomics? Several years ago, during my time as an employee of a multinational pharma company, I met a medical doctor and a…

R&D The general manager of Ferring Argentina believes that the country has one of the strongest social security systems in Latin America, with high reimbursement levels and coverage for most chronic and serious diseases, providing pharmaceutical companies a receptive environment for specialized medicines.     Could you please give us a…

clinical trials The general manager of Roche Argentina weighs up the factors that have allowed the country to be included among the top three performing markets in the region for Roche, and explains how the country has become an increasingly important location for clinical trials for the company.      What have…

OTC The general manager of Gennoma Laboratorios Argentina weighs up the factors of why raising brand awareness using public television is the key success to his company communication strategy.   When did Genomma first arrive in Argentina, and what is your strategy in the country today? Genomma Laboratories Argentina started in…

innovation Javier Anitua, Managing Director of Mylan Spain, discusses the preservation of Spain’s pharmacy model, preventive solutions for pharmacists, and the need for higher generic penetration in Spain.   What more needs to be done in Spain to communicate the value that generics bring to stakeholders who set prices? The sustainability…

regulation “We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says the President of PhAMA.    With the introduction of healthcare as one of the 12 National Key Economic Areas (NKEA)…

biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…

cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…